COVID-19 test approval: how to apply

How test manufacturers or distributors can apply for approval of their tests to sell on the UK market.

From 24 May 2023, the management of the Coronavirus (COVID-19) test device process (CTDA) moved from the UK Health Security Agency (UKHSA) to the Medicines and Healthcare products Regulatory Agency (MHRA). Applicants will be required to provide MHRA with the same data currently requested for all CTDA submissions.

Details of the changes are below.

Start a CTDA application.

Applications received up to 21 May 2023

Existing applications will remain with the UKHSA CTDA team. If you have any enquiries or updates, it's important that you continue to contact UKHSA at

Applications received on or after 24 May 2023

MHRA will manage all new applications submitted on or after 24 May 2023. New applicants from 24 May should email MHRA with any enquiries at

Manufacturers or distributors supplying COVID-19 tests must apply to the MHRA. Their product must meet the Medical Devices (Coronavirus Test Device Approvals) Regulations 2021.

During the approval process the MHRA will keep you updated on your application’s progress. This guide sets out each stage of the process you must follow.

Step 1: submit your application

After you submit your application, the MHRA will do a basic check to make sure it includes the required information to make sure that:

  • all the required fields on the application are complete
  • appropriate responses and attachments are included
  • you have paid the fee

The main areas of basic check are:

  • manufacturer and product information
  • regulatory status
  • product performance
  • biosafety
  • supplementary documents (for example, current version of the instructions for use, biosafety documents, evidence of performance characteristic)

For more details about how MHRA will assess your test, see COVID-19 test approval – step 2: process for desktop review.

Go to the Coronavirus (COVID-19) test device approvals service to begin your application for COVID-19 test approval.

Step 2: desktop review

This review assesses the evidence a supplier submits against a minimum required data set.

This step prevents products that are below the expected standards from progressing to the market as set out in the Medical Devices (Coronavirus Test Device Approvals) Regulations 2021. The assessment is done in 3 steps:

  1. A scientific adviser reviews it.
  2. The desktop review assurance group assesses the submission.
  3. The regulatory approvals committee then considers it.

The MHRA aims to provide an initial response or acknowledgement of receipt within 20 working days, but this may take longer if there’s a high volume of applications. They will prioritise certain applications where necessary, for example if it’s in the interests of public health.

If the MHRA need more information, you must respond in 20 working days. If you do not respond within 20 days, your application might be rejected.


You must pay for approval. The cost depends on the size of the company applying for validation. You can apply for the discounted price if your company has no more than 250 individuals in total.

Payment stage Full price Discounted price
Desktop review £14,000 £6,200

You can use the following types of payment:

  • credit or debit card
  • wallet payment

If you are having difficulty with the payment methods, email

A colleague will do their best to help you.

If you withdraw from the process after you have made the payment, it will not be refunded.

Fees are the same worldwide and are taken in GBP.

Outcome reporting

The MHRA only publishes details of tests that have passed, showing:

  • indicative performance category
  • name of test
  • name of manufacturer and business address
  • name and business address of person who made application (if different to the manufacturer)
  • date and version for instructions of use
  • type of test
  • date of approval
  • CE certification number
  • country of manufacture
  • sample type

Applicants appearing on the list must not use the name of the MHRA, or any Crown Body, to show preference to their products, services, or research.


Applicants who want to complain about the process should email

You must include a full summary of the complaint and any supporting information you consider relevant.


If your application is unsuccessful, you can request that the MHRA reconsider its decision, by using the web form in the service.

Published 28 July 2021
Last updated 24 May 2023 + show all updates
  1. Updated notice on change to the application process.

  2. Added notice explaining the upcoming change to the application process.

  3. Updated information about the desktop review.

  4. Updated email addresses.

  5. Added an email address ( for those having difficulty with the payment methods.

  6. Added link to 'COVID-19 test approval – step 2: process for desktop review'. Under 'Output reporting' added 'sample types' to the list of information that DHSC will publish for tests that have passed.

  7. Removed test performance guidance and technologies validation group guidance.

  8. First published.